IFN-α expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection

Virology

Volumn 396, Issue 1, 2010, Pages 59-68

  Li, Lianna ^a   Sherry, Barbara ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Cardiac fibroblast; Cardiac myocyte; Interferon; Myocarditis; Reovirus

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2 INTERFERON; ALPHA4 INTERFERON; ALPHA5 INTERFERON; ALPHA6 INTERFERON; ALPHA8 INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 7; INTERFERON STIMULATED GENE FACTOR 56; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL SPECIFICITY; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FETUS; FIBROBLAST CULTURE; HEART MUSCLE CELL; MAMMALIAN ORTHOREOVIRUS; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS MYOCARDITIS; VIRUS REPLICATION;

MURINAE; ORTHOREOVIRUS;

EID: 70649106805     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.10.013     Document Type: Article

References (65)

1. Austin B.A., James C.M., Harle P., and Carr D.J. Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol. Proced. Online 8 (2006) 55-62
2. Baig E., and Fish E.N. Distinct signature type I interferon responses are determined by the infecting virus and the target cell. Antivir. Ther. 13 3 (2008) 409-422
3. Bartlett E.J., Lenzo J.C., Sivamoorthy S., Mansfield J.P., Cull V.S., and James C.M. Type I IFN-beta gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis. Immunol. Cell Biol. 82 2 (2004) 119-126
4. Baty C.J., and Sherry B. Cytopathogenic effect in cardiac myocytes but not in cardiac fibroblasts is correlated with reovirus-induced acute myocarditis. J. Virol. 67 10 (1993) 6295-6298
5. Bautista E.M., Ferman G.S., Gregg D., Brum M.C., Grubman M.J., and Golde W.T. Constitutive expression of alpha interferon by skin dendritic cells confers resistance to infection by foot-and-mouth disease virus. J. Virol. 79 8 (2005) 4838-4847
6. Bergmann O., Bhardwaj R.D., Bernard S., Zdunek S., Barnabe-Heider F., Walsh S., Zupicich J., Alkass K., Buchholz B.A., Druid H., Jovinge S., and Frisen J. Evidence for cardiomyocyte renewal in humans. Science 324 5923 (2009) 98-102
7. Brandt E.R., Linnane A.W., and Devenish R.J. Expression of IFN A genes in subpopulations of peripheral blood cells. Br. J. Haematol. 86 4 (1994) 717-725
8. Civas A., Genin P., Morin P., Lin R., and Hiscott J. Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKKepsilon. J. Biol. Chem. 281 8 (2006) 4856-4866
9. Cull V.S., Bartlett E.J., and James C.M. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology 106 3 (2002) 428-437
10. Daffis S., Samuel M.A., Suthar M.S., Keller B.C., Gale Jr. M., and Diamond M.S. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J. Virol. 82 17 (2008) 8465-8475
11. Daliento L., Calabrese F., Tona F., Caforio A.L., Tarsia G., Angelini A., and Thiene G. Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J. Heart Lung. Transplant. 22 2 (2003) 214-217
12. Demoulins T., Baron M.L., Kettaf N., Abdallah A., Sharif-Askari E., and Sekaly R.P. Poly (I:C) induced immune response in lymphoid tissues involves three sequential waves of type I IFN expression. Virology 386 2 (2009) 225-236
13. Doolan A., Langlois N., and Semsarian C. Causes of sudden cardiac death in young Australians. Med. J. Aust. 180 3 (2004) 110-112
14. Esfandiarei M., and McManus B.M. Molecular biology and pathogenesis of viral myocarditis. Annu. Rev. Pathol. 3 (2008) 127-155
15. Foster G.R., Masri S.H., David R., Jones M., Datta A., Lombardi G., Runkell L., de Dios C., Sizing I., James M.J., and Marelli-Berg F.M. IFN-alpha subtypes differentially affect human T cell motility. J. Immunol. 173 3 (2004) 1663-1670
16. Foster G.R., Rodrigues O., Ghouze F., Schulte-Frohlinde E., Testa D., Liao M.J., Stark G.R., Leadbeater L., and Thomas H.C. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J. Interferon. Cytokine Res. 16 12 (1996) 1027-1033
17. Genin P., Lin R., Hiscott J., and Civas A. Differential regulation of human interferon-A genes expression by interferon regulatory factor 3 and 7. Mol. Cell. Biol. 29 12 (2009) 3435-3450
18. Grumbach I.M., Fish E.N., Uddin S., Majchrzak B., Colamonici O.R., Figulla H.R., Heim A., and Platanias L.C. Activation of the Jak-Stat pathway in cells that exhibit selective sensitivity to the antiviral effects of IFN-beta compared with IFN-alpha. J. Interferon. Cytokine Res. 19 7 (1999) 797-801
19. Hardy M.P., Owczarek C.M., Jermiin L.S., Ejdeback M., and Hertzog P.J. Characterization of the type I interferon locus and identification of novel genes. Genomics 84 2 (2004) 331-345
20. Hata N., Sato M., Takaoka A., Asagiri M., Tanaka N., and Taniguchi T. Constitutive IFN-alpha/beta signal for efficient IFN-alpha/beta gene induction by virus. Biochem. Biophys. Res. Commun. 285 2 (2001) 518-525
21. Heim A., and Weiss S. Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med. Microbiol. Immunol. 193 2-3 (2004) 149-154
22. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., and Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434 7034 (2005) 772-777
23. Huber S. Host immune responses to coxsackievirus B3. Curr. Top. Microbiol. Immunol. 323 (2008) 199-221
24. Izaguirre A., Barnes B.J., Amrute S., Yeow W.S., Megjugorac N., Dai J., Feng D., Chung E., Pitha P.M., and Fitzgerald-Bocarsly P. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74 6 (2003) 1125-1138
25. Jaks E., Gavutis M., Uze G., Martal J., and Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 366 2 (2007) 525-539
26. James C.M., Abdad M.Y., Mansfield J.P., Jacobsen H.K., Vind A.R., Stumbles P.A., and Bartlett E.J. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25 10 (2007) 1856-1867
27. Kawai T., and Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143 (2008) 1-20
28. Khabar K.S., Al-Haj L., Al-Zoghaibi F., Marie M., Dhalla M., Polyak S.J., and Williams B.R. Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J. Mol. Biol. 342 3 (2004) 833-846
29. Koerner I., Kochs G., Kalinke U., Weiss S., and Staeheli P. Protective role of beta interferon in host defense against influenza A virus. J. Virol. 81 4 (2007) 2025-2030
30. Koyama T., Sakamoto N., Tanabe Y., Nakagawa M., Itsui Y., Takeda Y., Kakinuma S., Sekine Y., Maekawa S., Yanai Y., Kurimoto M., and Watanabe M. Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol. Res. 34 1 (2006) 41-49
31. Kuhl U., Pauschinger M., Poller W., and Schultheiss H.P. Anti-viral treatment in patients with virus-induced cardiomyopathy. Ernst. Schering Res. Found Workshop 55 (2006) 323-342
32. Kuhl U., Pauschinger M., Schwimmbeck P.L., Seeberg B., Lober C., Noutsias M., Poller W., and Schultheiss H.P. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107 22 (2003) 2793-2798
33. Larrea E., Aldabe R., Riezu-Boj J.I., Guitart A., Civeira M.P., Prieto J., and Baixeras E. IFN-alpha5 mediates stronger Tyk2-stat-dependent activation and higher expression of 2′,5′-oligoadenylate synthetase than IFN-alpha2 in liver cells. J. Interferon. Cytokine Res. 24 8 (2004) 497-503
34. Lenzo J.C., Mansfield J.P., Sivamoorthy S., Cull V.S., and James C.M. Cytokine expression in murine cytomegalovirus-induced myocarditis: modulation with interferon-alpha therapy. Cell. Immunol. 223 1 (2003) 77-86
35. Loseke S., Grage-Griebenow E., Wagner A., Gehlhar K., and Bufe A. Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays. J. Immunol. Methods 276 1-2 (2003) 207-222
36. Marie I., Durbin J.E., and Levy D.E. Differential viral induction of distinct interferon-a genes by positive feedback through interferon regulatory factor-7. EMBO J. 17 (1998) 6660-6669
37. Miric M., Vasiljevic J., Bojic M., Popovic Z., Keserovic N., and Pesic M. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 75 6 (1996) 596-601
38. Mitani Y., Takaoka A., Kim S.H., Kato Y., Yokochi T., Tanaka N., and Taniguchi T. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6 7 (2001) 631-640
39. Montoya M., Schiavoni G., Mattei F., Gresser I., Belardelli F., Borrow P., and Tough D.F. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99 9 (2002) 3263-3271
40. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., and Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 264 5167 (1994) 1918-1921
41. Prakash A., Smith E., Lee C.K., and Levy D.E. Tissue-specific positive feedback requirements for production of type I interferon following virus infection. J. Biol. Chem. 280 19 (2005) 18651-18657
42. Puranik R., Chow C.K., Duflou J.A., Kilborn M.J., and McGuire M.A. Sudden death in the young. Heart. Rhythm. 2 12 (2005) 1277-1282
43. Sadler A.J., and Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8 7 (2008) 559-568
44. Sato M., Hata N., Asagiri M., Nakaya T., Taniguchi T., and Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441 1 (1998) 106-110
45. Schanen C., Chieux V., Lobert P.E., Harvey J., and Hober D. Correlation between the anti-virus-induced cytopathic effect activity of interferon-alpha subtypes and induction of MxA protein in vitro. Microbiol. Immunol. 50 1 (2006) 19-24
46. Schiff L.A., Nibert M.L., and Tyler K.L. Orthoreoviruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. Vol. 2 (2007), Lippincott Williams & Wilkins, Philadelphia, PA 1853-1915
47. Sherry B., Baty C.J., and Blum M.A. Reovirus-induced acute myocarditis in mice correlates with viral RNA synthesis rather than generation of infectious virus in cardiac myocytes. J. Virol. 70 10 (1996) 6709-6715
48. Sherry B., Torres J., and Blum M.A. Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins. J. Virol. 72 2 (1998) 1314-1323
49. Smith R.E., Zweerink H.J., and Joklik W.K. Polypeptide components of virions, top component and cores of reovirus type 3. Virology 39 4 (1969) 791-810
50. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311 (2006) 17-58
51. Stewart M.J., Smoak K., Blum M.A., and Sherry B. Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response. J. Virol. 79 5 (2005) 2979-2987
52. Stille-Siegener M., Heim A., and Figulla H.R. Subclassification of dilated cardiomyopathy and interferon treatment. Eur. Heart. J. 16 Suppl. O (1995) 147-149
53. Swaminathan N., Lai C.M., Beilharz M.W., Boyer S.J., and Klinken S.P. Biological activities of recombinant murine interferons alpha 1 and alpha 4: large difference in antiproliferative effect. Antiviral. Res. 19 2 (1992) 149-159
54. Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., Tanaka N., and Taniguchi T. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 288 5475 (2000) 2357-2360
55. Tovey M.G., Streuli M., Gresser I., Gugenheim J., Blanchard B., Guymarho J., Vignaux F., and Gigou M. Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc. Natl. Acad. Sci. U. S. A. 84 14 (1987) 5038-5042
56. van Boxel-Dezaire A.H., Rani M.R., and Stark G.R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25 3 (2006) 361-372
57. Van Heuvel M., Bosveld I.J., Mooren A.A., Trapman J., and Zwarthoff E.C. Properties of natural and hybrid murine alpha interferons. J. Gen. Virol. 67 Pt 10 (1986) 2215-2222
58. van Pesch V., Lanaya H., Renauld J.C., and Michiels T. Characterization of the murine alpha interferon gene family. J. Virol. 78 15 (2004) 8219-8228
59. Wang Y.X., da Cunha V., Vincelette J., White K., Velichko S., Xu Y., Gross C., Fitch R.M., Halks-Miller M., Larsen B.R., Yajima T., Knowlton K.U., Vergona R., Sullivan M.E., and Croze E. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am. J. Physiol. Heart. Circ. Physiol. 293 1 (2007) H69-76
60. Whitton J.L. Immunopathology during coxsackievirus infection. Springer Semin. Immunopathol. 24 2 (2002) 201-213
61. Woelk C.H., Frost S.D., Richman D.D., Higley P.E., and Kosakovsky Pond S.L. Evolution of the interferon alpha gene family in eutherian mammals. Gene 397 1-2 (2007) 38-50
62. Woodruff J.F. Viral myocarditis. A review. Am. J. Pathol. 101 2 (1980) 425-484
63. Yeow W.S., Lawson C.M., and Beilharz M.W. Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J. Immunol. 160 6 (1998) 2932-2939
64. Zoumbos N.C., Gascon P., Djeu J.Y., and Young N.S. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc. Natl. Acad. Sci. U. S. A. 82 1 (1985) 188-192
65. Zurney J., Howard K.E., and Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J. Virol. 81 24 (2007) 13668-13680